Eluxadoline is a mixed mu-opioid receptor agonist used to treat irritable bowel syndrome with diarrhea. The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system.
- Mechanism
- Curator reviewed
Eluxadoline is a mu-opioid receptor agonist, kappa opioid receptor agonist and a delta opioid receptor antagonist. Eluxadoline is used for diarrhea predominant IBS because it reduces intestinal contractility and normalizes stress-induced acceleration of upper GI transit. Antagonistic activity at the delta receptor minimizes the constipating effect usually seen by mu-opioid receptor agonists alone. Because of it's limited systemic bioavailability, there may be less side effects associated with the use of eluxadoline in comparison with other therapies used to treat diarrhea predominant IBS.
- Primary indication
- For the treatment of irritable bowel syndrome with diarrhea (IBS-D).Curator reviewed · 1 structured indication
- Formula / weight
- C32H35N5O5 · 569.662 g/mol (avg)
- First approval
- Canada, 2024 · United States, 2015
- Code names
- JNJ-27018966
- Brand names
Resolves to
QFNHIDANIVGXPE-FNZWTVRRSA-NSMILESCOC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Eluxadoline, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account